Establishment Labs Holdings, Inc. (ESTA)

In the past six months, Establishment Labs reported strong Q3 2025 financial results, exceeding expectations with an EPS of -$0.38 and revenue of $53.8 million, leading to an 8.3% pre-market stock increase. In December 2025, Establishment Labs submitted its Motiva implants to the FDA for approval in breast reconstruction, leading to analysts raising the price target. In January 2026, Establishment Labs announced preliminary unaudited financial results for Q4 and the full fiscal year 2025, expecting Q4 revenue between $64.0 million and $65.0 million, contributing to a full-year 2025 revenue of $210.5 million to $211.5 million.

Information regarding specific demand seasonality for Establishment Labs Holdings, Inc. products and services was not explicitly found. Elective procedures might be more popular during certain times of the year, but this is not confirmed for ESTA's specific product lines.

Establishment Labs Holdings, Inc. is a medical technology company focused on women's health, specifically in breast aesthetics and reconstruction, operating within the Healthcare sector. The company designs, develops, manufactures, and markets medical devices, including silicone gel-filled breast implants under the Motiva Implants® brand, the Motiva Flora® Tissue Expander, the Mia Femtech™ minimally invasive breast enhancement procedure, and the Puregraft line of products. The company emphasizes patient-focused safety, customization, and innovation in its product portfolio.

Establishment Labs Holdings, Inc. is headquartered in Alajuela, Costa Rica, and has a global presence, selling its products in over 80 to 90 countries. The company distributes its products through a combination of exclusive distributors and its direct sales force across Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and North America.

Establishment Labs has maintained a positive brand reputation due to its focus on product innovation, safety, and commitment to women's health. The company published 15 years of Motiva data in the 2025 Post-Market Surveillance Report, highlighting less than 1% device-related complications. The company also published Mia Femtech 3-year prospective study results in the Aesthetic Surgery Journal. Peter Caldini was appointed as Chief Executive Officer in May 2025. The company partnered with celebrity Meghan Trainor as a brand ambassador. Establishment Labs continued investment in research and development to improve product offerings and engage in clinical studies and strategic initiatives aimed at expanding market share and a commitment to patient safety.

Establishment Labs Holdings, Inc. has a mixed ownership structure, with institutional investors holding approximately 78.44% to 81.65% of the company's stock, and insiders owning around 18.35% to 19.75%. Retail and individual investors hold a smaller percentage, around 0.79% to 1.02%. Major institutional owners include JW Asset Management, LLC, RTW Investments, LP, and Brown Advisory Inc. A notable individual insider owner is Juan José Chacón-Quirós, who is also a founder and director of the company.